Keywords: novartis, plans, maintain, tight, grip, organ, transplantation
Novartis plans to maintain tight grip on organ transplantation market
Article | 11 October 1999
One of the key underpinnings of the success of Swiss life sciences groupNovartis has been its blockbusting immunosuppressant Sandimmun/Neoral ( ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Boehringer Ingelheim gets FDA warning letter on cGMP failures
- AstraZeneca's naloxegol meets endpoints; EMA validates Gilead's sofosbuvir MAA
- US FDA advisory panel backs approval of Merck & Co's suvorexant, but only at lower doses
- Italy's pharma market slump set to continue, warns GlobalData
- Is failure to adopt business process management putting the pharma industry at risk?
